Construction method and application of oncolytic adenovirus carrying anti-ROR1/anti-CD3 antibody gene
The invention discloses a construction method and application of an oncolytic adenovirus carrying an anti-ROR1/anti-CD3 bispecific antibody gene. The construction method comprises the following steps: respectively constructing a plasmid pcDNA3.1-antiROR1 scFv and a plasmid pcDNA3.1-antiCD3 scFv; the method comprises the following steps: constructing a plasmid pCA13-ROR1BITE; the method comprises the following steps: constructing a plasmid pSD55-ROR1BITE; the method comprises the following steps: constructing pAd-ROR1BITE; and packaging is carried out, such that the oncolytic adenovirus ZD55-ROR1BITE carrying the anti-ROR1/anti-CD3 bispecific antibody gene is obtained. The construction method of the oncolytic adenovirus provides a new thought and method for research of liver cancer, and the oncolytic adenovirus constructed by adopting the method has a remarkable inhibition effect on liver cancer cells, so that a technical basis is provided for research of drugs for treating liver cancer..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 05. Dez. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
WANG YIGANG [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-12-05, Last update posted on www.tib.eu: 2024-03-13, Last updated: 2024-03-22 |
|---|
| Patentnummer: |
CN117165628 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA00007506X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA00007506X | ||
| 003 | DE-627 | ||
| 005 | 20240322140922.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240315s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA00007506X | ||
| 035 | |a (EPA)CN117165628 | ||
| 035 | |a (EPA)88936665 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a WANG YIGANG |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Construction method and application of oncolytic adenovirus carrying anti-ROR1/anti-CD3 antibody gene |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-12-05, Last update posted on www.tib.eu: 2024-03-13, Last updated: 2024-03-22 | ||
| 520 | |a The invention discloses a construction method and application of an oncolytic adenovirus carrying an anti-ROR1/anti-CD3 bispecific antibody gene. The construction method comprises the following steps: respectively constructing a plasmid pcDNA3.1-antiROR1 scFv and a plasmid pcDNA3.1-antiCD3 scFv; the method comprises the following steps: constructing a plasmid pCA13-ROR1BITE; the method comprises the following steps: constructing a plasmid pSD55-ROR1BITE; the method comprises the following steps: constructing pAd-ROR1BITE; and packaging is carried out, such that the oncolytic adenovirus ZD55-ROR1BITE carrying the anti-ROR1/anti-CD3 bispecific antibody gene is obtained. The construction method of the oncolytic adenovirus provides a new thought and method for research of liver cancer, and the oncolytic adenovirus constructed by adopting the method has a remarkable inhibition effect on liver cancer cells, so that a technical basis is provided for research of drugs for treating liver cancer. | ||
| 650 | 4 | |a bio | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a C12N: Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media (microbiological testing media c12q0001000000) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a C12R: Indexing scheme associated with subclasses c12c-c12q, relating to microorganisms | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a ZHAN QI |4 aut | |
| 700 | 0 | |a LI QIANG |4 aut | |
| 700 | 0 | |a ZHANG HUILI |4 aut | |
| 700 | 0 | |a XIAO RONG |4 aut | |
| 700 | 0 | |a JIN HAO |4 aut | |
| 700 | 0 | |a WANG YING |4 aut | |
| 700 | 0 | |a JIA XIAOYUAN |4 aut | |
| 700 | 0 | |a HUANG BIAO |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 05. Dez. |
| 773 | 1 | 8 | |g year:2023 |g day:05 |g month:12 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/88936665/publication/CN117165628A1?q=CN117165628 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 05 |c 12 | ||